Industry / Canada
Canadian Province Not To Fund Avastin
March 2006 | Company Finance AlertThe Saskatchewan province of Canada has decided not to fund Roche/Genentech's Avastin (bevacizumab) for patients with advanced colorectal cancer because the monoclonal antibody's risks outweigh the benefits. According to government statement, Avastin only extends the lives of patients by only a few months, but it costs CAD36,000 (US$31,000) per patient per year. However, the drug is widely available in the US at a higher
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
